|
1
|
Wang LX, Li Y and Chen GZ: Network-based
co-expression analysis for exploring the potential diagnostic
biomarkers of metastatic melanoma. PLoS One. 13:e01904472018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cauci S, Maione V, Buligan C, Linussio M,
Serraino D and Stinco G: BsmI (rs1544410) and FokI (rs2228570)
vitamin D receptor polymorphisms, smoking, and body mass index as
risk factors of cutaneous malignant melanoma in northeast Italy.
Cancer Biol Med. 14:302–318. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
La Marra F, Stinco G, Buligan C, Chiriacò
G, Serraino D, Di Loreto C and Cauci S: Immunohistochemical
evaluation of vitamin D receptor (VDR) expression in cutaneous
melanoma tissues and four VDR gene polymorphisms. Cancer Biol Med.
14:162–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gandini S, Montella M, Ayala F, Benedetto
L, Rossi CR, Vecchiato A, Corradin MT, DE Giorgi V, Queirolo P,
Zannetti G, et al: Sun exposure and melanoma prognostic factors.
Oncol Lett. 11:2706–2714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bonin S, Albano A, di Meo N, Gatti A,
Stinco G, Zanconati F and Trevisan G: Cutaneous melanoma
frequencies and seasonal trend in 20 years of observation of a
population characterised by excessive sun exposure. Radiol Oncol.
49:379–385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Newton-Bishop JA, Davies JR, Latheef F,
Randerson-Moor J, Chan M, Gascoyne J, Waseem S, Haynes S, O'Donovan
C and Bishop DT: 25-Hydroxyvitamin D2/D3 levels and factors
associated with systemic inflammation and melanoma survival in the
Leeds melanoma cohort. Int J Cancer. 136:2890–2899. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
IARC, . International Agency for Research
on Cancer. http://monographs.iarc.fr/ENG/Classification/April
17–2019
|
|
9
|
Danielli R, Cisternino F, Giannarelli D,
Calabrò L, Camerini R, Savelli V, Bova G, Dragonetti R, Di Giacomo
AM, Altomonte M and Maio M: Long-term follow up of metastatic
melanoma patients treated with thymosin alpha-1: Investigating
immune checkpoints synergy. Expert Opin Biol Ther. 18 (Suppl
1):S77–S83. 2018. View Article : Google Scholar
|
|
10
|
Isvoranu G, Surcel M, Huică RI, Munteanu
AN, Pîrvu IR, Ciotaru D, Constantin C, Bratu O, Neagu M and
Ursaciuc C: Natural killer cell monitoring in cutaneous
melanoma-new dynamic biomarker. Oncol Lett. 17:4197–4206.
2019.PubMed/NCBI
|
|
11
|
Cecconi L, Busolin A, Barbone F, Serraino
D, Chiarugi A, Biggeri A and Catelan D: Spatial analysis of
incidence of cutaneous melanoma in the Friuli Venezia Giulia region
in the period 1995–2005. Geospat Health. 11:4222016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang AJ, Rambhatla PV and Eide MJ:
Socioeconomic and lifestyle factors and melanoma: A systematic
review. Br J Dermatol. 172:885–915. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
EUCAN (2012), . Malignant melanoma of the
skin. simpleecoiarcfr/eucan/Canceraspx?Cancer=202012 April
17–2019
|
|
15
|
The Italian Association of Cancer
Registries, AIRTUM Working Group. I numeri del cancro in
Italia-2018. 2018, http://registri-tumori.it/itacanApril
17–2019
|
|
16
|
AIRTUM (Associazione Italiana Registri
Tumori) Working Group, . Italian cancer figures-Report 2014.
Prevalence and cure of cancer in Italy. Epidemiol Prev. 38 (Suppl
1):S1–S144. 2014.
|
|
17
|
Piscitelli P, Neglia C, Falco A, Rivezzi
M, Agnello N, Argentiero A, Chitano G, Distante C, Della Rosa G,
Vinci G, et al: Melanoma in the Italian population and regional
environmental influences: A national retrospective survey on
2001–2008 hospitalization records. Int J Environ Res Public Health.
12:9102–9118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dinarello CA: Overview of the IL 1 family
in innate inflammation and acquired immunity. Immunol Rev.
281:8–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khazim K, Azulay EE, Kristal B and Cohen
I: Interleukin 1 gene and susceptibility to disease. Immunol Rev.
281:40–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mantovani A, Barajon I and Garlanda C:
IL-1 and IL-1 regulatory pathways in cancer progression and
therapy. Immunol Rev. 281:57–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Malik A and Kanneganti TD: Function and
regulation of IL-1α in inflammatory diseases and cancer. Immunol
Rev. 281:124–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garlanda C, Dinarello CA and Mantovani A:
The interleukin-1 family: Back to the future. Immunity.
39:1003–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cauci S, Guaschino S, De Aloysio D,
Driussi S, De Santo D, Penacchioni P and Quadrifoglio F:
Interrelationships of interleukin-8 with interleukin-1beta and
neutrophils in vaginal fluid of healthy and bacterial vaginosis
positive women. Mol Hum Reprod. 9:53–58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marriott HM, Gascoyne KA, Gowda R, Geary
I, Nicklin MJ, Iannelli F, Pozzi G, Mitchell TJ, Whyte MK, Sabroe I
and Dockrell DH: Interleukin-1β regulates CXCL8 release and
influences disease outcome in response to Streptococcus pneumoniae,
defining intercellular cooperation between pulmonary epithelial
cells and macrophages. Infect Immun. 80:1140–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo B, Zhang J and Fu S:
Inflammasomes/IL-1 pathways in myeloid cells modulate PD-1/PD-L1
checkpoint molecules. J Immunol. 198 (Suppl 1):S130.242017.
|
|
26
|
Rotte A, Bhandaru M, Zhou Y and McElwee
KJ: Immunotherapy of melanoma: Present options and future promises.
Cancer Metastasis Rev. 34:115–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coussens LM, Zitvogel L and Palucka AK:
Neutralizing tumor-promoting chronic inflammation: A magic bullet?
Science. 339:286–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qin Y, Ekmekcioglu S, Liu P, Duncan LM,
Lizée G, Poindexter N and Grimm EA: Constitutive aberrant
endogenous interleukin-1 facilitates inflammation and growth in
human melanoma. Mol Cancer Res. 9:1537–1550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Webb AC, Collins KL, Auron PE, Eddy RL,
Nakai H, Byers MG, Haley LL, Henry WM and Shows TB: Interleukin-1
gene (IL1) assigned to long arm of human chromosome 2. Lymphokine
Res. 5:77–85. 1986.PubMed/NCBI
|
|
30
|
Nicklin MJ, Weith A and Duff GW: A
physical map of the region encompassing the human interleukin-1
alpha, interleukin-1 beta, and interleukin-1 receptor antagonist
genes. Genomics. 19:382–384. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
El-Omar EM, Carrington M, Chow WH, McColl
KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N,
et al: Interleukin-1 polymorphisms associated with increased risk
of gastric cancer. Nature. 404:398–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Perri F, Piepoli A, Bonvicini C, Gentile
A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR,
Ricciardiello L, et al: Cytokine gene polymorphisms in gastric
cancer patients from two Italian areas at high and low cancer
prevalence. Cytokine. 30:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Liu C, Peng H, Zhang J and Feng
Q: IL1 receptor antagonist gene IL1-RN variable number of tandem
repeats polymorphism and cancer risk: A literature review and
meta-analysis. PLoS One. 7:e460172012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Broer PN, Aung T, Heidekrueger PI, Prantl
L and Narayan D: Divisive influence of interleukin-1 receptor
antagonist polymorphisms in melanoma patients. Clin Hemorheol
Microcirc. 67:319–326. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sokolenko AP and Imyanitov EN: Molecular
tests for the choice of cancer therapy. Curr Pharm Des.
23:4794–4806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gu F, Chen TH, Pfeiffer RM, Fargnoli MC,
Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, et al:
Combining common genetic variants and non-genetic risk factors to
predict risk of cutaneous melanoma. Hum Mol Genet. 27:4145–4156.
2018.PubMed/NCBI
|
|
37
|
Cauci S, Di Santolo M, Ryckman KK,
Williams SM and Banfi G: Variable number of tandem repeat
polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN:
A novel association with the athlete status. BMC Med Genet.
11:292010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fitzpatrick TB: The validity and
practicality of sun-reactive skin types I through VI. Arch
Dermatol. 124:869–871. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cauci S, Di Santolo M, Casabellata G,
Ryckman K, Williams SM and Guaschino S: Association of
interleukin-1beta and interleukin-1 receptor antagonist
polymorphisms with bacterial vaginosis in non-pregnant Italian
women. Mol Hum Reprod. 13:243–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Colombini A, Brayda-Bruno M, Lombardi G,
Croiset SJ, Ceriani C, Buligan C, Barbina M, Banfi G and Cauci S:
BsmI, ApaI and TaqI polymorphisms in the vitamin D receptor gene
(VDR) and association with lumbar spine pathologies: An Italian
case-control study. PLoS One. 11:e01550042016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zitvogel L, Kepp O, Galluzzi L and Kroemer
G: Inflammasomes in carcinogenesis and anticancer immune responses.
Nat Immunol. 13:343–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dinarello CA: Introduction to the
interleukin-1 family of cytokines and receptors: Drivers of innate
inflammation and acquired immunity. Immunol Rev. 281:5–7. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tarlow JK, Cork MJ, Clay FE,
Schmitt-Egenolf M, Crane AM, Stierle C, Boehncke WH, Eiermann TH,
Blakemore AI, Bleehen SS, et al: Association between interleukin-1
receptor antagonist (IL-1ra) gene polymorphism and early and
late-onset psoriasis. Br J Dermatol. 136:147–148. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tarlow JK, Blakemore AI, Lennard A, Solari
R, Hughes HN, Steinkasserer A and Duff GW: Polymorphism in human
IL-1 receptor antagonist gene intron 2 is caused by variable
numbers of an 86-bp tandem repeat. Hum Genet. 91:403–404. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Clay FE, Tarlow JK, Cork MJ, Cox A,
Nicklin MJ and Duff GW: Novel interleukin-1 receptor antagonist
exon polymorphisms and their use in allele-specific mRNA
assessment. Hum Genet. 97:723–726. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hishida A, Okugawa Y, Morimoto Y, Shirai
Y, Okamoto K, Momokita S, Ogawa A, Tanaka K, Nishikawa R, Toiyama
Y, et al: Genetic influence of cytokine polymorphisms on the
clinical outcome of Japanese gastrointestinal cancer patients in
palliative care. Oncol Lett. 17:623–629. 2019.PubMed/NCBI
|
|
48
|
Santtila S, Savinainen K and Hurme M:
Presence of the IL-1RA allele 2 (IL1RN*2) is associated with
enhanced IL-1beta production in vitro. Scand J Immunol. 47:195–198.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Danis VA, Millington M, Hyland VJ and
Grennan D: Cytokine production by normal human monocytes:
Inter-subject variation and relationship to an IL-1 receptor
antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol.
99:303–310. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rafiq S, Stevens K, Hurst AJ, Murray A,
Henley W, Weedon MN, Bandinelli S, Corsi AM, Guralnik JM, Ferrucci
L, et al: Common genetic variation in the gene encoding
interleukin-1-receptor antagonist (IL-1RA) is associated with
altered circulating IL-1RA levels. Genes Immun. 8:344–351. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reiner AP, Wurfel MM, Lange LA, Carlson
CS, Nord AS, Carty CL, Rieder MJ, Desmarais C, Jenny NS, Iribarren
C, et al: Polymorphisms of the IL1-receptor antagonist gene (IL1RN)
are associated with multiple markers of systemic inflammation.
Arterioscler Thromb Vasc Biol. 28:1407–1412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dewberry R, Holden H, Crossman D and
Francis S: Interleukin-1 receptor antagonist expression in human
endothelial cells and atherosclerosis. Arterioscler Thromb Vasc
Biol. 20:2394–2400. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hurme M and Santtila S: IL-1 receptor
antagonist (IL-1Ra) plasma levels are co-ordinately regulated by
both IL-1Ra and IL-1beta genes. Eur J Immunol. 28:2598–2602. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Buchs N, di Giovine FS, Silvestri T,
Vannier E, Duff GW and Miossec P: IL-1B and IL-1Ra gene
polymorphisms and disease severity in rheumatoid arthritis:
Interaction with their plasma levels. Genes Immun. 2:222–228. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bioque G, Crusius JB, Koutroubakis I,
Bouma G, Kostense PJ, Meuwissen SG and Peña AS: Allelic
polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra)
genes in inflammatory bowel disease. Clin Exp Immunol. 102:379–383.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Strandberg L, Lorentzon M, Hellqvist A,
Nilsson S, Wallenius V, Ohlsson C and Jansson JO: Interleukin-1
system gene polymorphisms are associated with fat mass in young
men. J Clin Endocrinol Metab. 91:2749–2754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ramírez-Pérez S, De la Cruz-Mosso U,
Hernández-Bello J, Martínez-Bonilla GE, Ramírez-Dueñas MG,
Pereira-Suárez AL, Parra Rojas I, Martínez-López E, Macías-Barragán
J and Muñoz-Valle JF: High expression of interleukin-1 receptor
antagonist in rheumatoid arthritis: Association with IL1RN*2/2
genotype. Autoimmunity. 50:468–475. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Živković M, Kolić I, Jesić S, Jotić A and
Stanković A: The allele 2 of the VNTR polymorphism in the gene that
encodes a natural inhibitor of IL-1β, IL-1RA is favorably
associated with chronic otitis media. Clin Exp Otorhinolaryngol.
11:118–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Singh M, Mansuri MS, Jadeja SD, Marfatia
YS and Begum R: Association of interleukin 1 receptor antagonist
intron 2 variable number of tandem repeats polymorphism with
vitiligo susceptibility in Gujarat population. Indian J Dermatol
Venereol Leprol. 84:285–291. 2018.PubMed/NCBI
|
|
60
|
Acuner Ozbabacan SE, Gursoy A, Nussinov R
and Keskin O: The structural pathway of interleukin 1 (IL-1)
initiated signaling reveals mechanisms of oncogenic mutations and
SNPs in inflammation and cancer. PLoS Comput Biol. 10:e10034702014.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Le TT, Skak K, Schroder K, Schroder WA,
Boyle GM, Pierce CJ and Suhrbier A: IL-1 contributes to the
anti-cancer efficacy of ingenol mebutate. PLoS One.
11:e01539752016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kattan MW, Hess KR, Amin MB, Lu Y, Moons
KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, et
al: American Joint Committee on Cancer acceptance criteria for
inclusion of risk models for individualized prognosis in the
practice of precision medicine. CA Cancer J Clin. 66:370–374. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Keller HR, Zhang X, Li L, Schaider H and
Wells JW: Overcoming resistance to targeted therapy with
immunotherapy and combination therapy for metastatic melanoma.
Oncotarget. 8:75675–75686. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yu Y and Cui J: Present and future of
cancer immunotherapy: A tumor microenvironmental perspective. Oncol
Lett. 16:4105–4113. 2018.PubMed/NCBI
|
|
66
|
Abbasian MH, Abbasi B, Ansarinejad N,
Motevalizadeh Ardekani A, Samizadeh E, Gohari Moghaddam K and
Hashemi MR: Association of interleukin-1 gene polymorphism with
risk of gastric and colorectal cancers in an Iranian population.
Iran J Immunol. 15:321–328. 2018.PubMed/NCBI
|
|
67
|
Qiao J, Jia QN and Jin HZ: Lack of
association of the IL-1RN and IL-10 polymorphisms with risk of
psoriasis: A meta-analysis. Mol Genet Genomic Med. 7:e005122019.
View Article : Google Scholar : PubMed/NCBI
|
